Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Митральная недостаточность

Список литературы

  1. Mann DL, Zipes DP, Libby P et al. Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine; 2014.
  2. Земцовский Э.В., Гордеев М.Л., Малев Э.Г. Клапанные пороки сердца. В книге: Кардиология. Национальное руководство. Москва, 2015. С. 582-604.
  3. Земцовский Э.В., Малев Э.Г., Березовская Г.А. и др. Наследственные нарушения соединительной ткани в кардиологии. Диагностика и лечение. Российские рекомендации (первый пересмотр). Российский кардиологический журнал. 2013; № 99(приложение 1): 1–32.
  4. Малев Э.Г., Пшепий А.Р., Васина Л.В. и др. Ремоделирование миокарда и диастолическая дисфункция левого желудочка при пролапсе митрального клапана. Российский кардиологический журнал. 2013;(2):12-17.
  5. Del Forno, B., De Bonis, M., Agricola, E. et al. Mitral valve regurgitation: a disease with a wide spectrum of therapeutic options. Nature Rev Cardiol (2020). https://doi.org/10.1038/s41569-020-0395-7.
  6. Hakim F.A., Kendall C.B., Alharthi M., et al. (2010) Parachute mitral valve in adults-a systematic overview. Echocardiography 27:581–586.
  7. Chehab O, Roberts-Thomson R, Ng Yin Ling C, et al. Secondary mitral regurgitation: pathophysiology, proportionality and prognosis. Heart. 2020;106(10):716-723. doi: 10.1136/heartjnl-2019-316238.
  8. Iung B, Vahanian A. Epidemiology of acquired valvular heart disease. Can J Cardiol. 2014;30(9):962-70. https://doi.org/10.1016/j.cjca.2014.03.022.
  9. Freed LA, Benjamin EJ, Levy D, et al. Mitral valve prolapse in the general population: the benign nature of echocardiographic features in the Framingham Heart Study // J Am Coll Cardiol 2002: Vol. 40: 1298–1304.
  10. Bursi F, Enriquez-sarano M, Jacobsen SJ, Roger VL. Mitral regurgitation after myocardial infarction: a review. Am J Med. 2006;119(2):103-12.
  11. Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol. 2015;65(12):1231-1248.
  12. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 2022;43(7):561-632.
  13. Otto CM, Nishimura RA, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease. J Am Coll Cardiol 2020;77:450-500.
  14. Carpentier A. Cardiac valve surgery--the “French correction” J Thorac Cardiovasc Surg. 1983;86:323–337.
  15. Z-N Hong, J-S Huang, L-Q Huang, H Cao, Q. Chen. The effect of valve noise on the quality of life of patients after mechanical mitral valve replacement in a Chinese population. . Journal of Cardiothoracic Surgery (2019) 14:137 https://doi.org/10.1186/s13019-019-0956-1.
  16. S. Kueri, F. A. Kari, R. A. Fuentes, H-H. Sievers et al. The Use of Biological Heart Valves. Deutsches √Дrzteblatt International  Dtsch Arztebl Int 2019; 116: 423-30, DOI: 10.3238/arz tebl.2019.0423
  17. N. Glaser, J. Liska, J. Hultman, P. Svenarud. Early Bioprosthetic Mitral Valve Failure Due to Fusion of the Cusps. Ann Thorac Surg 2013;96:699-701.
  18. Helmut Baumgartner, Volkmar Falk, Jeroen J Bax, Michele De Bonis, Christian Hamm, Per Johan Holm, Bernard Iung, Patrizio Lancellotti, Emmanuel Lansac, Daniel Rodriguez Muñoz, Raphael Rosenhek, Johan Sjögren, Pilar Tornos Mas, Alec Vahanian, Thomas Walther, Olaf Wendler, Stephan Windecker, Jose Luis Zamorano, ESC Scientific Document Group , 2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 38 (36): 2739–2791.
  19. S. Shahida, S, Aouabdi, Z.A. Taher, A.E. Alghamdi, M.A. Ahmed, F.A. Ahmed, S.Alghamdi, A. Haneef. The Prevalence and Predictors of Atherosclerotic Coronary Artery Disease in Rheumatic and Non-rheumatic Valvular Heart Disease Patients. Cureus. 2024. 16 (3).
  20. McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Michael Bohm, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal.2021; 42 (36): 3599-3726.
  21. Clavel MA, Tribouilloy C, Vanoverschelde JL, et al. Association of B-Type Natriuretic Peptide With Survival in Patients With Degenerative Mitral Regurgitation. J Am Coll Cardiol. 2016;68(12):1297-307.
  22. Bäck M, Pizarro R, Clavel MA. Biomarkers in Mitral Regurgitation. Prog Cardiovasc Dis. 2017;60(3):334-341.
  23. Nishimura R. A., Otto C. M,. Bonow R. O, Carabello B. A., Erwin  J.P. III, Fleisher L.A., Jneid H. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e1159-e1195.
  24. Baumgartner H. The Challenge of Timing Surgery in Degenerative Mitral Regurgitation: Is B-Type Natriuretic Peptide the Solution? J Am Coll Cardiol. 2016;68(12):1308-11.
  25. Kwon JM, Kim KH, Akkus Z, Jeon KH, Park J, Oh BH. Artificial intelligence for detecting mitral regurgitation using electrocardiography. J Electrocardiol. 2020;59:151-157.
  26. Bax JJ, Di Carli M, Narula J, Delgado V. Multimodality imaging in ischaemic heart failure. Lancet. 2019;393(10175):1056-1070.
  27. Sadeghian H, Lotfi-Tokaldany M, Montazeri M, et al. Early Improvement in Mitral Regurgitation after Cardiac Resynchronization Therapy in Cardiomyopathy Patients. J Heart Valve Dis. 2017;26(5):557-563.
  28. Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for Noninvasive Evaluation of Native Valvular Regurgitation: A Report from the American Society of Echocardiography Developed in Collaboration with the Society for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr. 2017;30(4):303-371.
  29. Doherty JU, Kort S, Mehran R, et al. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2017 Appropriate Use Criteria for Multimodality Imaging in Valvular Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Soc Echocardiogr. 2018;31(4):381-404.
  30. Cimino S, Guarracino F, Valenti V, et al. Echocardiography and Correction of Mitral Regurgitation: An Unbreakable Link. Cardiology. 2020;145(2):110-120.
  31. Malev E, Reeva S, Vasina L, et al. Cardiomyopathy in young adults with classic mitral valve prolapse. Cardiol Young. 2014;24(4):694-701.
  32. Malev E., Mitrofanova L., Zemtsovsky E., Kim G. Preoperative left ventricular function in degenerative mitral valve disease. Journal of Cardiovascular Medicine. 2014. Т. 15. № 3. С. 222-229.
  33. Tribouilloy C, Grigioni F, Avierinos JF, et al. Survival implication of left ventricular end-systolic diameter in mitral regurgitation due to flail leaflets a long-term follow-up multicenter study. J Am Coll Cardiol. 2009; 54:1961–1968.
  34. Thomas JD, Kinno M. The Prognostic Role of Global Longitudinal Strain in Severe Primary Mitral Regurgitation: Moving Past the Proof-of-Concept Era. JACC Cardiovasc Imaging. 2018;11(9):1245-1247.
  35. Namazi F, Van der bijl P, Hirasawa K, et al. Prognostic Value of Left Ventricular Global Longitudinal Strain in Patients With Secondary Mitral Regurgitation. JAmCollCardiol. 2020;75(7):750-758.
  36. Бокерия Л.А., Косарева Т.И., Куц Э.В., Макаренко В.Н., Мироненко В.А. Оценка ремоделирования полостей сердца при патологии митрального клапана методами эхокардиографии и магнитно-резонансной томографии. Бюллетень НЦССХ им. А.Н. Бакулева РАМН Сердечно-сосудистые заболевания. 2013. Т. 14. № 3. С. 19-26.
  37. Gaasch WH, Meyer TE. Secondary mitral regurgitation (part 1): volumetric quantification and analysis. Heart. 2018;104(8):634-638.
  38. Nicoara A, Skubas N, Ad N, et al. Guidelines for the Use of Transesophageal Echocardiography to Assist with Surgical Decision-Making in the Operating Room: A Surgery-Based Approach: From the American Society of Echocardiography in Collaboration with the Society of Cardiovascular Anesthesiologists and the Society of Thoracic Surgeons. J Am Soc Echocardiogr. 2020;33(6):692-734.
  39. Corrigan FE, Maini A, Reginauld S, Lerakis S. Contemporary evaluation of mitral regurgitation - 3D echocardiography, cardiac magnetic resonance, and procedural planning. Expert Rev Cardiovasc Ther. 2017;15(9):715-725.
  40. Uretsky S, Argulian E, Narula J, Wolff SD. Use of Cardiac Magnetic Resonance Imaging in Assessing Mitral Regurgitation: Current Evidence. J Am Coll Cardiol. 2018;71(5):547-563.
  41. Dulgheru R, Marchetta S, Sugimoto T, et al. Exercise Testing in Mitral Regurgitation. Prog Cardiovasc Dis. 2017;60(3):342-350.
  42. Magne J., Mahjoub H., Dulgheru R., et al. (2014) Left ventricular contractile reserve in asymptomatic primary mitral regurgitation. Eur Heart J. 35:1608-1616.
  43. Ghoreishi M., Evans C.F., deFilippi C.R., et al. (2011) Pulmonary hypertension adversely affects short- and long-term survival after mitral valve operation for mitral regurgitation: implications for timing of surgery. J Thorac Cardiovasc Surg 142:1439–1452.
  44. Apostolakis EE, Baikoussis NG. Methods of estimation of mitral valve regurgitation for the cardiac surgeon. J Cardiothorac Surg. 2009;4:34
  45. Dongshan Zhu, Hsin-Fang Chung, Annette J Dobson et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health. 2019 Nov;4(11):e553-e564.
  46. Løkkegaard E, Jovanovic Z, Heitmann BL et al. The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy. Maturitas. 2006 Jan 20;53(2):226-33.
  47. Muka T, Oliver-Williams C, Kunutsor S et al. Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis JAMA Cardiol. 2016 Oct 1;1(7):767-776.
  48. Lobo RA, Pickar JH, Stevenson JC, Mack WJ, Hodis HN. Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis. 2016 Nov; 254:282-290.
  49. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;
  50. Watanabe N. Acute mitral regurgitation. Heart. 2019;105(9):671-677.
  51. Ahmed M.I., Aban I., Lloyd S.G., et al. A randomized controlled phase IIb trial of beta(1)-receptor blockade for chronic degenerative mitral regurgitation. J Am Coll Cardiol. 2012; 60:833–838.
  52. Harris K.M., Aeppli D.M., Carey C.F. Effects of angiotensin-converting enzyme inhibition on mitral regurgitation severity, left ventricular size, and functional capacity. Am Heart J 2005;150:1106.
  53. Borer JS, Sharma A. Drug Therapy for Heart Valve Diseases. Circulation. 2015;132(11):1038-45.
  54. Asgar AW, Mack MJ, Stone GW. Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol. 2015;65(12):1231-1248.
  55. Kang DH, Park SJ, Shin SH, et al. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation. Circulation. 2019;139(11):1354-1365.
  56. McMurray JJV., Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde A-M Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. September 19, 2019. doi: 10.1056/NEJMoa1911303.
  57. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Bohm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M,  Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPERORReduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383:1413-1424.
  58. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9.
  59. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(37):3627-3639. doi: 10.1093/eurheartj/ehad195.
  60. van Bommel R.J., Marsan N.A., Delgado V., et al. Cardiac resynchronization therapy as a therapeutic option in patients with moderate-severe functional mitral regurgitation and high operative risk. Circulation 2011;124:912–919.
  61. Enriquez-Sarano M, Schaff HV, Orszulak TA, Tajik AJ, BaileyKR, Frye RL. Valve repair improves the outcome of surgery for mitral regurgitation: a multivariate analysis. Circulation 1995;91:1022–8.
  62. Enriquez-Sarano M, Tajik AJ, Schaff HV, Orszulak TA, Bailey KR, Frye RL. Echocardiographic prediction of survival after surgical correction of organicmitral regurgitation. Circulation 1994;90:830–837.
  63. Badhwar V, Peterson ED, Jacobs JP, He X, Brennan JM, O’Brien SM, DokholyanRS, George KM, Bolling SF, Shahian DM, Grover FL, Edwards FH, Gammie JS.Longitudinal outcome of isolated mitral repair in older patients: results from14,604 procedures performed from 1991 to 2007. Ann ThoracSurg 2012;94:1870–1877; discussion 1877–1879
  64. Nishimura RA, O’Gara PT, Bavaria JE, Brindis RG, Carroll JD, Kavinsky CJ, Lindman BR, Linderbaum JA, Little SH, Mack MJ, Mauri L, Miranda WR, Shahian DM, Sundt TM III. 2018 AATS/ACC/ASE/SCAI/STS expert consensus systems of care document: a proposal to optimize care for patients with valvular heart disease: a joint report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J ThoracCardiovasc Surg. 2019;157:XXX–XX
  65. Le Tourneau T, Richardson M, Juthier F, Modine T, Fayad G, Polge AS, EnnezatPV, Bauters C, Vincentelli A, Deklunder G. Echocardiography predictors andprognostic value of pulmonary artery systolic pressure in chronic organic mitralregurgitation. Heart 2010;96:1311–1317
  66. Enriquez-Sarano M, Tajik AJ, Schaff HV, Orszulak TA, McGoon MD, Bailey KR, Frye RL. Echocardiographic prediction of left ventricular function after correction of mitral regurgitation: results and clinical implications. J Am CollCardiol1994;24:1536–1543.
  67. Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, Smalling RW, Siegel R, Rose GA, Engeron E, Loghin C, Trento A, Skipper ER, Fudge T, Letsou GV, Massaro JM, Mauri L, EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011;364:13951406.
  68. Feldman T, Kar S, Elmariah S, Smart SC, Trento A, Siegel RJ, Apruzzese P, Fail P, Rinaldi MJ, Smalling RW, Hermiller JB, Heimansohn D, Gray WA, Grayburn PA, Mack MJ, Lim DS, Ailawadi G, Herrmann HC, Acker MA, Silvestry FE, Foster E, Wang A, Glower DD, Mauri L, EVEREST II Investigators. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol 2015;66:28442854. 
  69. Buzzatti N, Van Hemelrijck M, Denti P, Ruggeri S, Schiavi D, Scarfo IS, Reser D, Taramasso M, Weber A, La Canna G, De Bonis M, Maisano F, Alfieri O. Transcatheter or surgical repair for degenerative mitral regurgitation in elderly patients: a propensity-weighted analysis. J Thorac Cardiovasc Surg 2019;158:8694 e81. 
  70. Sorajja P, Vemulapalli S, Feldman T, Mack M, Holmes DR, Jr., Stebbins A, Kar S, Thourani V, Ailawadi G. Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT Registry Report. J Am Coll Cardiol 2017;70:23152327
  71. Iung B, Armoiry X, Vahanian A, Boutitie F, Mewton N, Trochu JN, Lefevre T, Messika-Zeitoun D, Guerin P, Cormier B, Brochet E, Thibault H, Himbert D, Thivolet S, Leurent G, Bonnet G, Donal E, Piriou N, Piot C, Habib G, Rouleau F, Carrie D, Nejjari M, Ohlmann P, Saint Etienne C, Leroux L, Gilard M, Samson G, Rioufol G, Maucort-Boulch D, Obadia JF, MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years. Eur J Heart Fail 2019;21:16191627.
  72. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ, COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 2018;379:23072318.
  73.  Obadia JF, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, Lefevre T, Piot C, Rouleau F, Carrie D, Nejjari M, Ohlmann P, Leclercq F, Saint Etienne C, Teiger E, Leroux L, Karam N, Michel N, Gilard M, Donal E, Trochu JN, Cormier B, Armoiry X, Boutitie F, Maucort-Boulch D, Barnel C, Samson G, Guerin P, Vahanian A, Mewton N, MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 2018;379:22972306
  74. Acker MA, Parides MK, Perrault LP, Moskowitz AJ, Gelijns AC, Voisine P, SmithPK, Hung JW, Blackstone EH, Puskas JD, Argenziano M, Gammie JS, Mack M,Ascheim DD, Bagiella E, Moquete EG, Ferguson TB, Horvath KA, Geller NL,Miller MA, Woo YJ, D’Alessandro DA, Ailawadi G, Dagenais F, Gardner TJ,O’Gara PT, Michler RE, Kron IL. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med 2014;370:23–32
  75. Mihaljevic T, Lam BK, Rajeswaran J, Takagaki M, Lauer MS, Gillinov AM,Blackstone EH, Lytle BW. Impact of mitral valve annuloplasty combined withrevascularization in patients with functional ischemic mitral regurgitation. J AmCollCardiol 2007;49:2191–2201
  76. Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM.Impact ofmitral valve annuloplasty on mortality risk in patients with mitral regurgitationand left ventricular systolic dysfunction.J Am CollCardiol 2005;45:381–387
  77. Daniel H. Steinberg, Sameer Gafoor, Horst Sievert. Эндоваскулярные вмешательства при недостаточности митрального клапана. В кн.: Алекян Б.Г. (ред.). Рентгенэндоваскулярная хирургия. Национальное Руководство. М.: Литтерра; 2017: 154-165
  78. Mack MJ, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant BK, Grayburn PA, Rinaldi MJ, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Rogers JH, Marx SO, Cohen DJ, Weissman NJ, Stone GW, COAPT Investigators. 3-Year outcomes of transcatheter mitral valve repair in patients with heart failure. J Am Coll Cardiol 2021; 77:1029-1040.
  79. Adamo M, Fiorelli F, Melica B, D’Ortona R, Lupi L, Giannini C, Silva G, Fiorina C, Branca L, Chiari E, Chizzola G, Spontoni P, Espada Guerreiro C, Curello S, Petronio AS, Metra M COAPT-like profile predicts long-term outcomes in patients with secondary mitral regurgitation undergoing MitraClip implantation. JACC Cardiovasc Interv 2021; 14:15-25.
  80. Iung B, Messika-Zeitoun D, Boutitie F, Trochu JN, Armoiry X, Maucort-Boulch D, Obadia JF, Vahanian A. Characteristics and outcome of COAPT-eligible patients in the MITRA-FR Trial. Circulation 2020; 142:2482-2484.
  81. Tischler MD, Cooper KA, Rowen M, LeWinter MM. Mitral valve replacement versus mitral valve repair: a Doppler and quantitative stress echocardiographic study. Circulation 1994;89:132–7.
  82. Feindel CM, Tufail Z, David TE, Ivanov J, Armstrong S. Mitralvalve surgery in patients with extensive calcification of the mitral annulus. J ThoracCardiovascSurg 2003;126:777– 82.
  83. Gillinov AM, Cosgrove DM, Lytle BW, et al. Reoperation for failure of mitral valve repair. J ThoracCardiovascSurg 1997;113:467–73.
  84. Gillinov AM, Cosgrove DM, Blackstone EH, et al. Durability of mitral valve repair for degenerative disease. J ThoracCardiovascSurg 1998;116:734–43.
  85. Gillinov AM, Cosgrove DM. Mitral valve repair for degenerative disease. J Heart Valve Dis 2002;11Suppl 1:S15–S20.
  86. Mohty D, Enriquez-Sarano M. The long-term outcome of mitral valve repair for mitral valve prolapse. CurrCardiol Rep 2002;4:104–10.
  87. Hennein HA, Swain JA, McIntosh CL, Bonow RO, Stone CD, Clark RE. Comparative assessment of chordal preservation versus chordal resection during mitral valve replacement. J ThoracCardiovascSurg 1990; 99: 828 –36.
  88. Rozich JD, Carabello BA, Usher BW, Kratz JM, Bell AE, ZileMR.Mitral valve replacement with and without chordal preservation inpatients with chronic mitral regurgitation: mechanisms for differences in postoperative ejection performance. Circulation 1992;86:1718–26.
  89. Horskotte D, Schulte HD, Bircks W, Strauer BE. The effect of chordal preservation on late outcome after mitral valve replacement: a randomized study. J Heart Valve Dis 1993;2:150–8.
  90. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C,Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanicalversus a bioprosthetic valve: final report of the Veterans Affairs randomizedtrial. J Am CollCardiol 2000;36:1152–1158.
  91. Oxenham H, Bloomfield P, Wheatley DJ, Lee RJ, Cunningham J, Prescott RJ,Miller HC.Twenty year comparison of a Bjork-Shiley mechanical heart valvewith porcine bioprostheses. Heart 2003;89:715–721.
  92. Stassano P, Di Tommaso L, Monaco M, IorioF, Pepino P, Spampinato N, VosaC. Aortic valve replacement: a prospective randomized evaluation of mechanicalversus biological valves in patients ages 55 to 70 years. J Am CollCardiol2009;54:1862–1868.
  93. Craver JM, Cohen C, Weintraub WS. Case-matched comparison of mitral valve replacement and repair. Ann ThoracSurg 1990;49:964–9.
  94. David TE, Omran A, Armstrong S, Sun Z, Ivanov J. Long-termresults of mitral valve repair for myxomatous disease with andwithoutchordal replacement with expanded polytetrafluoroethylene sutures. J ThoracCardiovascSurg 1998;115:1279–85.
  95. Duran CM. Surgical techniques for the repair of anterior mitral leaflet prolapse.Card Surg 1999; 14:471– 81. 325
  96. Alfieri O, Maisano F, De Bonis M, et al. The double-orificetechnique in mitral valve repair: a simple solution for complex problems. J ThoracCardiovascSurg 2001;122:674–81.
  97. Burkhart HM, Orszulak TA. Complicated mitral valve repairs.Cardiol Rev 2001;9:106 –11.
  98. Dreyfus GD, Bahrami T, Alayle N, Mihealainu S, Dubois C, DeLentdecker P. Repair of anterior leaflet prolapse by papillary muscle repositioning: a new surgical option. Ann ThoracSurg 2001;71:1464–70.
  99. Alfieri O, Elefteriades JA, Chapolini RJ, et al. Novel suture device or beating heart mitral leaflet approximation. Ann ThoracSurg 2002;74:1488 –93.
  100. Gaasch WH, John RM, Aurigemma GP. Managing asymptomatic patients with chronic mitral regurgitation. Chest 1995;108:842–7.
  101. Ross J Jr. The timing of surgery for severe mitral regurgitation. N Engl J Med 1996; 335:1456–8.
  102. Carabello BA, Crawford FA Jr. Valvular heart disease. N Engl J Med 1997;337:32– 41.
  103. Crawford MH, Souchek J, Oprian CA, et al. Determinants of survival and left ventricular performance after mitral valve replacement: Department of Veterans Affairs Cooperative Study on ValvularHeart Disease. Circulation 1990;81:1173– 81.
  104. Phillips HR, Levine FH, Carter JE, et al. Mitral valve replacement for isolated mitral regurgitation: analysis of clinical course and late postoperative left ventricular ejection fraction. Am J Cardiol 1981;48:647–54.
  105. Wisenbaugh T, Skudicky D, Sareli P. Prediction of outcome after valve replacement for rheumatic mitral regurgitation in the era of chordal preservation. Circulation 1994;89:191–7.
  106. Bolling SF, Pagani FD, Deeb GM, Bach DS. Intermediate-term outcome of mitral reconstruction in cardiomyopathy.J ThoracCardiovascSurg 1998; 115:381– 6.
  107. Chen FY, Adams DH, Aranki SF, et al. Mitral valve repair in cardiomyopathy. Circulation 1998; 98:II124 –27.
  108. Bishay ES, McCarthy PM, Cosgrove DM, et al. Mitral valve surgery in patients with severe left ventricular dysfunction. EurJCardiothoracSurg 2000; 17:213–21.
  109. Bolling SF. Mitral reconstruction in cardiomyopathy. J Heart ValveDis 2002;11Suppl 1:S26 –S31.
  110. Badhwar V, Bolling SF. Mitral valve surgery in the patient with leftventricular dysfunction. SeminThoracCardiovascSurg 2002;14:133–6.
  111. Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM. Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am CollCardiol 2005;45:381–7.
  112. Capomolla S, Febo O, Gnemmi M, et al. Beta-blockade therapy inchronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J 2000;139:596–608.
  113. Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the Multisite STimulationIn Cardiomyopathy (MUSTIC) study. J Am CollCardiol 2002;40:111– 8.
  114. Breithardt OA, Sinha AM, Schwammenthal E, et al. Acute effectsof cardiac resynchronization therapy on functional mitral regurgitation in advanced systolic heart failure. J Am CollCardiol 2003;41:765–70.
  115. St John Sutton MG, Plappert T, Abraham WT, et al. Effect ofcardiac resynchronization therapy on left ventricular size and functionin chronic heart failure. Circulation 2003;107:1985–90.
  116. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 2005;352:875– 83.
  117. Rosenhek R, Rader F, Klaar U, et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation 2006;113:2238–44.
  118. Malik AH, Yandrapalli S, Aronow WS, Panza JA, Cooper HA. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves. Heart (British Cardiac Society). 2019;105(18):1432-6.
  119. Duan L, Doctor JN, Adams JL, Romley JA, Nguyen LA, An J, et al. Comparison of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and bioprosthetic heart valves. The American journal of cardiology. 2021;146:22-8.
  120. Pasciolla S, Zizza LF, Le T, Wright K. Comparison of the efficacy and safety of direct oral anticoagulants and warfarin after bioprosthetic valve replacements. Clin Drug Investig. 2020;40(9):839-45.
  121. Russo V, Carbone A, Attena E, Rago A, Mazzone C, Proietti R, et al. Clinical benefit of direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart valves. Clin Ther. 2019;41(12):2549-57.
  122. Karthikeyan G, Senguttuvan NB, Joseph J, Devasenapathy N, Bahl VK, Airan B.Urgent surgery compared with fibrinolytic therapy for the treatment of leftsidedprosthetic heart valve thrombosis: a systematic review and meta-analysis of observational studies. Eur Heart J 2013;34:1557-1566.
  123. Simonato M, Whisenant B, Ribeiro HB, et al. Transcatheter mitral valve replacementafter surgical repair or replacement: comprehensive midterm evaluationof valve-in-valve and valve-in-ring implantation from the VIVID Registry. Circulation 2021;143:104-116.
  124. Alkhouli M, Rihal CS, Zack CJ, Eleid MF, Maor E, Sarraf M, Cabalka AK, ReederGS, Hagler DJ, Maalouf JF, Nkomo VT, Schaff HV, Said SM. Transcatheter andsurgical management of mitral paravalvular leak: long-term outcomes. JACCCardiovasc Interv. 2017;10:1946-1956.
  125. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska-Gosciniak E, Price S, Roos-Hesselink J, Snygg-Martin U, Thuny F, Tornos Mas P, Vilacosta I, Zamorano JL; ESC Scientific Document Group. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075-3128.
  126. Sardo S, Osawa EA, Finco G, Gomes Galas FRB, de Almeida JP, Cutuli SL, Frassanito C, Landoni G, Hajjar LA. Nitric Oxide in Cardiac Surgery: A Meta-Analysis of Randomized Controlled Trials. J Cardiothorac Vasc Anesth. 2018 Dec;32(6):2512-2519. doi: 10.1053/j.jvca.2018.02.003.
  127. Tessler J, Bordoni B. Cardiac Rehabilitation. 2022. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 30725881
  128. Mezzani A., Hamm L.F., Jones A.M., et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: A joint position statement of the European association for cardiovascular  prevention and rehabilitation, the American association of cardiovascular and pulmonary rehabilitation and  the  Canadian association of cardiac rehabilitation. Eur J Prev Cardiol. 2013;20:442-467.
  129. Scottish Intercollegiate Guidelines Network (SIGN). Cardiac rehabilitation. Edinburgh: SIGN; 2016.
  130. Приказ Министерства здравоохранения РФ от 31 июля 2020 г. N 778н "О Порядке организации медицинской реабилитации взрослых" Зарегистрировано в Минюсте РФ 25 сентября 2020 г. Регистрационный № 60039 https://www.garant.ru/products/ipo/prime/doc/74581688/
  131. Ambrosetti M., Abreu A., Corrà U., et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. European Journal of Preventive Cardiology. 2021; 28: 460-495.
  132. Butchart E.G., Gohlke-Barwolf C., Antunes M.J., et al. Recommendations for the management of patients after heart valve surgery. Eur HeartJ. 2005;26(22):2463–2471. doi: 10.1093/eurheartj/ehi426
  133. Sibilitz  K.L., Berg S.K., Tang L.H., et al. Exercise-based cardiac rehabilitation for adults after heart valve surgery. Cochrane Database Syst Rev. 2016;3:CD010876. doi: 10.1002/14651858.CD010876.pub2.
  134. Anderson L., Sharp G.A., Norton R.J., et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database of Systematic Reviews. 2017;6:CD007130.
  135. Thomas R.J., Beatty A.L., Beckle T.M., et al. Home-based cardiac rehabilitation: a scientific statement from the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology. Circulation. 2019;140:e69-e89.
  136. Kanejima Y, Shimogai T, Kitamura M, Ishihara K, Izawa KP. Effect of Early Mobilization on Physical Function in Patients after Cardiac Surgery: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2020;17(19):7091.
  137. Sahar W, Ajaz N, Haider Z, Jalal A. Effectiveness of Pre-operative Respiratory Muscle Training versus Conventional Treatment for Improving Post operative Pulmonary Health after Coronary Artery Bypass Grafting. Pak J Med Sci. 2020;36(6):1216-1219.
  138. Borregaard B, Dahl JS, Riber LPS, Ekholm O, Sibilitz KL, Weiss M, Sørensen J, Berg SK, Møller JE. Effect of early, individualised and intensified follow-up after open heart valve surgery on unplanned cardiac hospital readmissions and all-cause mortality. Int J Cardiol. 2019;289:30-36.
  139. Nechwatal R.M. Cardiac rehabilitation after surgical and transcatheter valve replacement and repair. Dtsch Z Sportmed.2018;69:285-292.
  140. Kraal J.J., Van den Akker-Van Marle M.E., Abu-Hanna A., et al. Clinical and cost-effectiveness of home-based cardiac rehabilitation compared to conventional, centre-based cardiac rehabilitation: results of the FIT@Home study. Eur J Prev Cardiol. 2017;24:1260-1273.
  141. Thomas R.J., Balady G., Banka G., et al. 2018 ACC/AHA Clinical Performance and Quality Measures for Cardiac Rehabilitation: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2018;71(16):1814-1837.
  142. Иванова Г.Е., Мельникова Е.В., Шмонин А.А., Вербицкая Е.В., Аронов Д.М., Белкин А.А., Беляев А.Ф., Бодрова Р.А., Бубнова М.Г., Буйлова Т.В., Мальцева М.Н., Мишина И.Е., Нестерин К.В., Никифоров В.В., Прокопенко С.В., Сарана А.М., Стаховская Л.В., Суворов А.Ю., Хасанова Д.Р., Цыкунов М.Б. Применение международной классификации функционирования в процессе медицинской реабилитации. Вестник восстановительной медицины. 2018;6(88):2-77.
  143. https://www.icf-research-branch.org/download/send/12-cardiovascularandrespiratoryconditions/156-brief-icf-core-set-for-cardiopulmonary-conditions-in-acute-care
  144. https://www.icf-research-branch.org/download/send/12-cardiovascularandrespiratoryconditions/162-brief-icf-core-set-for-cardiopulmonary-conditions-in-post-acute-care
  145. Sommaruga M., Angelino E., Della Porta P., et al. Best practice in psychological activities in cardiovascular prevention and rehabilitation: Position Paper. Monaldi  Arch Chest Dis. 2018; 88(2): 966. doi:10.4081/monaldi.2018.966.
  146. Visseren F.L.J., Mach F., Smulders Y.M., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484.
  147. Ambrosetti M., Abreu A., Cornelissen V., et al. Delphi consensus recommendations on how to provide cardiovascular rehabilitation in the COVID-19 era. Eur J Prev Cardiol. 2021;28(5):541-557.
  148. Fletcher G.F., Ades P.A., Kligfield P., et al. Exercise Standards for Testing and Training A Scientific Statement From the American Heart Association. Circulation. 2013;128:873-934. doi:10.1161/CIR.0b013e31829b5b44.
  149. Opasich C., De Feo S., Pinna G.D., et al. Distance walked in the 6-minute test soon after cardiac surgery: toward an efficient use in the individual patient. Chest. 2004;126(6):1796-1801. doi:10.1378/chest.126.6.1796. PMID: 15596676.
  150. Meurin P.,  Iliou M.C.,  Driss A.B., et al.Early exercise training after mitral valve repair: a multicentric prospective French study. Chest. 2005;128(3):1638-44. doi: 10.1378/chest.128.3.1638.
  151. Nechwatal R.M. Cardiac rehabilitation after surgical and transcatheter valve replacement and repair. Dtsch Z Sportmed.2018;69:285-292. doi:10.5960/dzsm.2018.343.
  152. Приказ Министерства здравоохранения РФ от 28 сентября 2020 г. № 1029н “Об утверждении перечней медицинских показаний и противопоказаний для санаторно-курортного лечения”
  153. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635–641.
  154. MokCK, BoeyJ, WangR, ChanTK, CheungKL, LeePK, ChowJ, NgRP, TseTF. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the preventionof prosthetic heart valve thromboembolism: a prospective randomizedclinical trial. Circulation 1985;72:1059–1063.
  155. Massel DR, Little SH. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 2013:CD003464.
  156. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170:1433.
  157. Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012;379:322-334.
  158. Raffaele De Caterina, Stefan Agewall, Felicita Andreotti et all. Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. European Heart Journal. 2022. 43(37): 3512–3527. 
  159. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:2423–2434.
  160. Pocar M, Di mauro A, Passolunghi D, et al. Predictors of adverse events after surgical ventricular restoration for advanced ischaemic cardiomyopathy. Eur J Cardiothorac Surg. 2010;37(5):1093-100.
  161. Кардиология: национальное руководство: под ред. Е. В. Шляхто. 2-е изд., перераб. И доп. М.: ГЭОТАР-Медиа, 2015. 800 с
  162. Руководство по кардиологии: под ред. акад. Е. И. Чазова. В 4 т. М.: Издательский дом «Практика», 2014.
  163. Poelaert JI, Bouchez S. Perioperative echocardiographic assessment of mitral valve regurgitation: a comprehensive review. Eur J Cardiothorac Surg. 2016;50(5):801-812.
  164. Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for evaluation of prosthetic valves with echocardiography and doppler ultrasound: a report From the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves. J Am Soc Echocardiogr. 2009;22(9):975-1014.
  165. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381.
  166. Munro J., Booth A., Nicholl J. Routine preoperative testing: a systematic review of the evidence. Health Technology Assessment (Winchester, England). 1997. 1(12): i-iv; 1.
  167. Macpherson D. S. Preoperative laboratory testing: should any tests be" routine" before surgery? Medical Clinics of North America. 1993. 77 (2): 289-308.
  168. Mohan M. et al. Preoperative screening of HIV, HBV, HCV essential for surgical team and patients both–A research study in Department of Surgery, Tertiary Care Institute of North India, Rohilkhand Medical College and Hospital, Bareilly (UP) India //Int J Contemp Med Res (Online). 2018. 5 (7): G1-G4.
  169. Сокольская М. А., Бокерия О. Л. Алгоритм предоперационного обследования и подготовка к операции пациентов с приобретенными пороками сердца. Бюллетень НЦССХ им. АН Бакулева РАМН. Сердечно-сосудистые заболевания. 2017. 18(6): 46-46.
  170. Заболотских И. Б., Баялиева А.Ж., Григорьев С.В., Киров М.Ю., К.М. Лебединский К.М. Периоперационное ведение пациентов с сопутствующей патологией клапанного аппарата сердца. Вестник интенсивной терапии имени АИ Салтанова.  2016. 3: 55-69.
  171. Edwards A. F., Forest D. J. Preoperative laboratory testing. Anesthesiology clinics. 2018. 36(4): 493-507.
  172. Еременко А. А. Медикаментозное лечение острой сердечной недостаточности: что есть и что нас ждет. Вестник анестезиологии и реаниматологии.  2020. 17(2): 29-37.
  173. Пчелина И.В., Пляс О.А., Бондарь В.Ю. Реабилитация больных кардиохирургического профиля в системе обязательного медицинского страхования.Вестник общественного здоровья и здравоохранения Дальнего Востока России. 2015. 3:1-11.
  174. Alaour B, Menexi C, Shah BN. Clinical and echocardiographic follow-up of patients following surgical heart valve repair or replacement: a tertiary centre experience. Echo Res Pract. 2018;5(3):113-119.
  175. Cai B. et al. N‐terminal pro‐Brain natriuretic peptide as a useful biomarker for monitoring prognosis in patients with cardiac valve replacement. Journal of Clinical Laboratory Analysis. – 2011. – Т. 25. – №. 3. – С. 149-155.
  176. Çelik A, Altay H, Azap A, Çavuşoğlu Y, Nalbantgil S, Şenol E, Temizhan A, Yılmaz MB. Vaccination of adults with heart failure and chronic heart conditions: Expert opinion. Turk Kardiyol Dern Ars. 2018;46(8):723-734.
  177. Landoni G. [и др.]. Volatile Anesthetics versus Total Intravenous Anesthesia for Cardiac Surgery // New England Journal of Medicine. 2019. № 13 (380).
  178. Рыбка М.М., Хинчагов Д.Я., Мумладзе К.В., Никулкина Е.С. Под ред. Л.А.Бокерия. Протоколы анестезиологического обеспечения рентгенэндоваскулярных и диагностических процедур, выполняемых у кардиохирургических пациентов различных возрастных групп. Методические рекомендации. М.:НЦССХ им.А.Н.Бакулева РАМН; . 2018.
  179. Gropper MA, Miller RD, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Cohen LH, et al. (7 October 2019). Miller's Anesthesia (9th ed.). Philadelphia, PA: Elsevier. ISBN 978-0-323-61264-7.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*